Cargando…
Does Risk-Adapted Proton Beam Therapy Have a Role as a Complementary or Alternative Therapeutic Option for Hepatocellular Carcinoma?
To evaluate the role of risk-adapted proton beam therapy (PBT) in hepatocellular carcinoma (HCC) patients, a total of 243 HCC patients receiving risk-adapted PBT with three dose-fractionation regimens (regimen A [n = 40], B [n = 60], and C [n = 143]) according to the proximity of their gastrointesti...
Autores principales: | Kim, Tae Hyun, Park, Joong-Won, Kim, Bo Hyun, Kim, Hyunjung, Moon, Sung Ho, Kim, Sang Soo, Woo, Sang Myung, Koh, Young-Hwan, Lee, Woo Jin, Kim, Dae Yong, Kim, Chang-Min |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406298/ https://www.ncbi.nlm.nih.gov/pubmed/30781391 http://dx.doi.org/10.3390/cancers11020230 |
Ejemplares similares
-
Phase II Study of Hypofractionated Proton Beam Therapy for Hepatocellular Carcinoma
por: Kim, Tae Hyun, et al.
Publicado: (2020) -
Phase I Dose-Escalation Study of Proton Beam Therapy for Inoperable Hepatocellular Carcinoma
por: Kim, Tae Hyun, et al.
Publicado: (2015) -
Optimal time of tumour response evaluation and effectiveness of hypofractionated proton beam therapy for inoperable or recurrent hepatocellular carcinoma
por: Kim, Tae Hyun, et al.
Publicado: (2017) -
Proton Beam Therapy for Treatment-Naïve Hepatocellular Carcinoma and Prognostic Significance of Albumin-Bilirubin (ALBI) Grade
por: Kim, Tae Hyun, et al.
Publicado: (2022) -
Effectiveness and Safety of Simultaneous Integrated Boost-Proton Beam Therapy
for Localized Pancreatic Cancer
por: Kim, Tae Hyun, et al.
Publicado: (2018)